Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

European Psychiatry

Volumn 27, Issue 7, 2012, Pages 518-521

  Levkovitz, Y ^a,b   Alpert, J E ^b   Brintz, C E ^b   Mischoulon, D ^b   Papakostas, G I ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cognitive function; Major depression; One carbon cycle; Pharmacotherapy; S adenosylmethionine

Indexed keywords

PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; SECONDARY ANALYSIS;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; S-ADENOSYLMETHIONINE; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84866465151     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.03.006     Document Type: Article

References (31)

1. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
2. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001, 178:200-206.
3. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opin Investig Drugs 1997, 6:417-426.
4. Bottiglieri T., Laundy M., Martin R., Carney M.W., et al. S-adenosylmethionine influences monoamine metabolism. Lancet 1984, 2(8396):224.
5. Castaneda A.E., Suvisaari J., Marttunen M., Perälä J., et al. Cognitive functioning in a population-based sample of young adults with a history of non-psychotic unipolar depressive disorders without psychiatric comorbidity. J Affect Disord 2008, 110:36-45.
6. Chan A., Tchantchou F., Graves V., Rozen R., et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine. J Nutr Health Aging 2008, 12:252-261.
7. Erb C., Klein J. Enhancement of brain choline levels by nicotinamide: mechanism of action. Neurosci Lett 1988, 249:111-114.
8. Fava M., Graves L.M., Benazzi F., Scalia M.J., et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006, 67:1754-1759.
9. Fava M., Iosifescu D.V., Pedrelli P., Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009, 78:91-97.
10. Fennig S., Mottes A., Ricter-Levin G., Treves I., et al. Everyday memory and laboratory memory tests: general function predictors in schizophrenia and remitted depression. J Nerv Ment Dis 2002, 190:677-682.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders - Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. 1976, 338-376. National Institute of Mental Health, Rockville, MD.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
14. Hammer A., Ardel G. Cognitive functioning in major depression - a summary. Front Hum Neurosci 2009, 3(26):1-7.
15. Hirata F., Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980, 209:1082-1090.
16. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006, 145:39-48.
17. Kennedy N., Foy K., Sherazi R., McDonough M., et al. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord 2007, 9:25-37.
18. Mischoulon D., Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002, 76:1158S-1161S.
19. Mischoulon D., Fava M. Are nutritional supplements ready for prime time?. J Clin Psychiatry 2008, 69:1497-1498.
20. Muccioli G., Scordamaglia A., Bertacco S., Di Carlo R. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 1992, 227:293-299.
21. Panza F., Frisardi V., Capurso C., D'Introno A., et al. Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and Alzheimer's disease. J Alzheimers Dis 2009, 16:467-470.
22. Papakostas G.I, Alpert J.E., Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep 2003, 5:460-466.
23. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors (SRIs) for SRI-non-responders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942-8.
24. Pavia J., Martos F., Gonzalez-Correa J.A., Garcia A.J., et al. Effect of S-adenosyl methionine on muscarinic receptors in young rats. Life Sci 1997, 60:825-832.
25. Remington R., Chan A., Paskavitz J., Shea T.B. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 2009, 24:27-33.
26. Shea T.B., Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. Am J Alzheimers Dis 2008, 13:67-70.
27. Taylor Tavares J.V., Drevets W.C., Sahakian B.J. Cognition in mania and depression. Psychol Med 2003, 33:959-967.
28. Tchantchou F., Graves M., Ortiz D., Chan A., et al. S-adenosyl methionine: a connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease. J Nutr Health Aging 2006, 10:541-544.
29. Trivedi M.H., Hollander E., Nutt D., Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008, 69:246-258.
30. Williams A.C., Ramsden D.B. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. Med Hypotheses 2005, 65:353-362.
31. Williams A.L., Girard C., Jui D., Sabina A., et al. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005, 28:132-139.